Mind-mapping for lung cancer: Towards a personalized therapeutics approach

Advances in Therapy

Volumn 28, Issue 3, 2011, Pages 173-194

  Mollberg, N ^a   Surati, M ^b   Demchuk, C ^b   Fathi, R ^b   Salama, A K ^c   Husain, A N ^b   Hensing, T ^b,d   Salgia, R ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Lung cancer; Mind mapping; Nonsmall cell lung cancer; Personalized medicine

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ASBESTOS; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FUSION PROTEIN EML4 ALK; GEFITINIB; K RAS PROTEIN; NAVELBINE; ONCOPROTEIN; RADON; UNCLASSIFIED DRUG;

ALK GENE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CHEMICAL CARCINOGENESIS; EML4 ALK GENE; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGICAL DATA; FUSION GENE; GENE MUTATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; OCCUPATIONAL EXPOSURE; ONCOGENE; ONCOGENE K RAS; PERSONALIZED MEDICINE; PROGNOSIS; REVIEW; SMOKING; SOCIAL STATUS; TREATMENT PLANNING;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS;

EID: 79958128509     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0103-9     Document Type: Review

References (128)

1. Buzan T, Buzan B. The Mind Map Book. London: BBC Books; 1993.
2. D'Antoni AV, Zipp GP, Olson VG, Cahill TF. Does the mind map learning strategy facilitate information retrieval and critical thinking in medical students? BMC Med Educ. 2010;10:61.
3. Farrand P, Hussain F, Hennessy E. The efficacy of the 'mind map' study technique. Med Educ. 2002;36:426-431.
4. Wickramasinghe A, Widanapathirana N, Kuruppu O, Liyanage I, Karunathilake I. Effectiveness of mind maps as a learning tool for medical students. South East Asian J Med Educ. 2007;1:30-32.
5. Eppler MJ. A comparison between concept maps, mind maps, conceptual diagrams, and visual metaphors as complementary tools for knowledge construction and sharing. Information Visualization. 2006;5:202-210. (Pubitemid 44359517)
6. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute; Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Accessed September 28, 2010.
7. Cancer Facts and Figures 2010. Available at: http://www.cancer.org/acs/ groups/content/@nho/documents/document/acspc-024113.pdf. Accessed September 28, 2010.
8. Health Service, Centers for Disease Control and Prevention, Washington, DC 2010. Smoking and tobacco use - fact sheets. Available at: http://www.cdc.gov/tobacco/data-statistics/fact-sheets/. Accessed May 4, 2010.
9. Alberg AJ, Nonemaker J. Who is at high risk for lung cancer? Population-level and individuallevel perspectives. Semin Respir Crit Care Med. 2008;29:223-232. (Pubitemid 351748428)
10. Burns, DM. Cigarette smoking. In: Comprehensive Textbook of Thoracic Oncology, Aisner J, et al (eds), Williams and Wilkins; Baltimore 1996:51.
11. US Department of Health and Human Services. The Health Benefits of Smoking Cessation: a Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990. Available at http://www.hhs.gov/. Accessed April 5, 2010.
12. Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung cancer risk. JAMA 2005;294:1505-1510. (Pubitemid 41362687)
13. Shaten BJ, Kuller LH, Kjelsberg MO, et al. Lung cancer mortality after 16 years in MRFIT participants in intervention and usual-care groups. Multiple Risk Factor Intervention Trial. Ann Epidemiol. 1997;7:125-136.
14. Han B, Gfroerer JC, Colliver JD. Associations between duration of illicit drug use and health conditions: results from the 2005-2007 National Surveys on Drug Use and Health. Ann Epidemiol. 2010;20:289-297.
15. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. Br Med J. 1997;315:980-988. (Pubitemid 27443125)
16. Brüske-Hohlfeld, I. Environmental and occupational risk factors for lung cancer. Methods Mol Biol. 2009;472:3-23.
17. American Cancer Society. What causes small cell lung cancer? Available at: http://www.cancer.org/. Accessed May 19, 2010.
18. National Cancer Institute. Asbestos exposure and cancer risk. Available at: http://www.cancer.gov/cancertopics/factsheet/Risk/asbestos. Accessed May 20, 2010.
19. van Loon AJ, Goldbohm RA, Kant IJ, Swan GMH, Kremer AM, van den Brandt PA. Socioeconomic status and lung cancer incidence in men in the Netherlands: is there a role for occupational exposure? J Epidemiol Community Health. 1997;51:24-29.
20. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer. 2005;93:825-833. (Pubitemid 41486445)
21. Prochazka M, Hall P, Gagliardi G, et al. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol. 2005;23:7467-7474. (Pubitemid 46291809)
22. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497-1505.
23. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168:1097-1103. (Pubitemid 351749227)
24. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5-8. (Pubitemid 30055895)
25. Goodman GE, Thornquist MD, Balmes J, et al. The beta-carotene and retinol efficacy trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping betacarotene and retinol supplements. J Natl Cancer Inst. 2004;96:1743-1750. (Pubitemid 39654568)
26. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130:561-565.
27. Kubík A, Polák J. Lung cancer detection. Results of a randomized prospective study in Czechloslovakia. Cancer. 1986;57:2427-2437.
28. Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest. 1984;86:44-53.
29. National Lung Screening Trial (NLST). Available at: http:// clinicaltrials.gov/. Accessed May 26, 2010.
30. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer. 2007;120:868-874. (Pubitemid 46175408)
31. Steiling K, Ryan J, Brody JS, Spira A. The field of tissue injury in the lung and airway. Cancer Prev Res. 2008;1:396-403.
32. Roy HK, Subramanian H, Damania D, et al. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010;70:7748-7754.
33. van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer. 2010;102:27-34.
34. Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax. 2008;63:377-383. (Pubitemid 351497954)
35. Bach P. Overdiagnosis in lung cancer: different perspectives, definitions, implications. Thorax. 2008;63:298-300. (Pubitemid 351497939)
36. Travis WD, Brambilla E, Muller-Hermlink HK, Harris CC, eds. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
37. Rodenhuis S, Slebos RJC, Boot AJM, et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res. 1988;48:5738-5741.
38. Barsky SH, Grossman DA, Ho J, Holmes EC. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol. 1994;7:633-640.
39. Breathnach OS, Kwiatkowski DJ, Finkelstein DM, et al. Bronchioloalveolar carcinoma of the lung: recurrences and survival in patients with stage I disease. J Thorac Cardiovasc Surg. 2001;121:42-47. (Pubitemid 32105322)
40. Barsky SH, Cameron R, Osann KE, Tomita D, Holmes EC. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer. 1994;73:1163-1170.
41. Liebow, AA. Bronchiolo-alveolar carcinoma. Adv Intern Med.1960;10:329-358.
42. Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res. 1998;58:328-333. (Pubitemid 28047075)
43. Maziak De, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221-228.
44. Luke WP, Pearson FG, Todd TR, et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg. 1986;91:53-56. (Pubitemid 16126367)
45. Vilmann P, Krasnick M, Larsen SS, Jacobsen GK, Clementsen P. Transesophageal endoscopic ultrasound-guided fine needle aspiration (EUSFNA) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS): a combined approach in the evaluation of mediastinal lesions. Endoscopy. 2005;37:833-839. (Pubitemid 41263956)
46. National Comprehensive Cancer Network (NCCN) Guidelines in Oncology: Non-Small Cell Carcinoma. Available at: http://www.nccn.org/professionals/ physician-gls/PDF/nscl.pdf. Accessed August 20, 2010.
47. Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(suppl. 3):78S-93S.
48. Ou SH, Zell JA, Anton-Culver H. Prognostic factors for survival of stage 1 nonsmall cell lung cancer patients: a population based analysis of 19, 702 stage 1 patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110:1532-1541.
49. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl. 3):234S-242S.
50. Doddoli C, D'Journo B, Le Pimpec-Barthes F, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg. 2005;80:2032-2040. (Pubitemid 41718023)
51. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360. (Pubitemid 38101630)
52. Daniels LJ, Balderson SS, Onaitis MW, et al. Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. Ann Thorac Surg. 2002;74:860-864. (Pubitemid 35001818)
53. Mckenna RJ, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. Ann Thorac Surg. 2006;81:421-426. (Pubitemid 43120529)
54. Watanabe Y, Shimizu J, Hayashi Y, et al. Results of surgical treatment on patients with stage IIIA non-small lung cancer. Thorac Cardiovasc Surg. 1991;39:44-49.
55. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Intern J Radiat Oncol Biol Phys. 2002;54:365-369. (Pubitemid 35286799)
56. Taylor NA, Liao ZX, Cox JD, et al. Equivalent outcome of patients with clinical stage IIIA nonsmall cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by resection. Int J Radiat Oncol Biol Phys. 2004;58:204-212. (Pubitemid 38016222)
57. van Meerbeeck JP, Kramer GW, Van Schil PE, et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442-450. (Pubitemid 47073567)
58. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl. 3):243S-265S.
59. Patterson GA, Piazza D, Pearson FG, et al. Significance of metastatic disease in subaortic lymph nodes. Ann Thorac Surg. 1987;43:155-159.
60. Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422-428.
61. Pairolero PC, Trastek VF, Payne WS. Treatment of bronchogenic carcinoma with chest wall invasion. Surg Clin North Am. 1987;67:959-964. (Pubitemid 17158577)
62. Piehler JM, Pairolero PC, Weiland LH, Offord KP, Payne WS, Bernatz PE. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg. 1982;34:684-691. (Pubitemid 13208212)
63. Harpole DH Jr, Healey EA, DeCamp MM Jr, Mentzer SJ, Strauss GM, Sugarbaker DJ. Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system. Ann Surg Oncol. 1996;3:261-269.
64. McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg. 1985;89:836-841. (Pubitemid 15012851)
65. Port JL, Korst RJ, Lee PC, Kansler AL, Kerem Y, Altorki NK. Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg. 2007;83:397-400.
66. Osaki T, Sugio K, Hanagiri T, et al. Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg. 2003;75:1745-1751. (Pubitemid 36677206)
67. Nagai K, Sohara Y, Tsuchiya R, Goya T, Miyaoka E; Japan Lung Cancer Registration Committee. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol. 2007;2:282-286. (Pubitemid 47181709)
68. de Perrot M, Fadel E, Mussot S, de Palma A, Chapelier A, Dartevelle P. Resection of locally advanced (T4) non-small cell lung cancer with cardiopulmonary bypass. Ann Thorac Surg. 2005;79:1691-1696.
69. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:1880-1892.
70. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007;25:313-318. (Pubitemid 350003020)
71. Komaki R, Mountain CF, Holbert JM, et al. Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. Int J Radiat Oncol Biol Phys. 1990;19:31-36. (Pubitemid 20239781)
72. Mountain CF. Expanded possibilities for surgical treatment of lung cancer: survival in stage IIIA disease. Chest. 1990;97:1045-1051. (Pubitemid 20166788)
73. Hu C, Chang EL, Hassenbusch SJ 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis Cancer. 2006;106:1998-2004.
74. Mintz A, Perry J, Spithoff K, Chambers A, Laperriere N. Management of single brain metastasis: a practice guideline. Curr Oncol. 2007;14:131-143.
75. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500. (Pubitemid 20067825)
76. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491. (Pubitemid 43854963)
77. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring EML4-ALK. J Clin Oncol. 2009;27:4247-4253.
78. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
79. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251-6266.
80. West H, Lilenbaum R, Harpole D, Wozniak A, Sequist L. Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. J Thorac Oncol. 2009;4(9 suppl. 2):S1029-S1039.
81. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med. 1987;317:929-935. (Pubitemid 17147935)
82. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991;6:1353-1362. (Pubitemid 21924231)
83. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561-565. (Pubitemid 20260082)
84. Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst. 1999;91:2032-2038.
85. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res. 2008;14:5731-5734.
86. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131-139. (Pubitemid 40188446)
87. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001;19:448-457. (Pubitemid 32112858)
88. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-smallcell lung cancer. J Clin Oncol. 1999;17:668-675. (Pubitemid 29075256)
89. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007;25:5240-5247. (Pubitemid 350232256)
90. Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008;26:1472-1478.
91. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909.
92. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer. 2003;41(suppl. 1):S29-S42. (Pubitemid 36818993)
93. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139. (Pubitemid 38637993)
94. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500. (Pubitemid 38720929)
95. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer. 2006;118:257-262. (Pubitemid 41779062)
96. Pietanza M, D'Angelo SP, Johnson ML, et al. EGFR mutations in men and cigarette smokers with lung adenocarcinoma [abstract]. Clin Oncol. 2010;28(suppl.):15S. Abstract 10538.
97. Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science. 2007;98:1817-1824. (Pubitemid 350002184)
98. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2:e313.
99. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226-235. (Pubitemid 40070814)
100. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell. 2006;9:485-495. (Pubitemid 43832191)
101. Cox G, Jones JL, O'Byrne KJ. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000;6:2349-2355. (Pubitemid 30399202)
102. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 2000;7:603-607.
103. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer. 1998;77:663-669. (Pubitemid 28059477)
104. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer. 2004;91:208-212. (Pubitemid 39037060)
105. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858-2865. (Pubitemid 27330013)
106. Pfeiffer P, Clausen PP, Andersen K, Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-smallcell lung cancer: an immunohistochemical study on cryosections. Br J Cancer 1996;74:86-91. (Pubitemid 26231983)
107. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515-522. (Pubitemid 27211827)
108. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552. (Pubitemid 46733081)
109. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-5899.
110. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol. 2004;22:777-784. (Pubitemid 41103588)
111. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol. 2004;22:785-794. (Pubitemid 41103589)
112. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831-3837. (Pubitemid 46630729)
113. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-132. (Pubitemid 41058344)
114. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7:169-181.
115. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448:561-566. (Pubitemid 47206930)
116. Takahashi T, Sonobe M, Koboyashi M, et al. Clinicopathologic features of non-small cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17:889-897.
117. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009;115:1723-1733.
118. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14:4275-4283.
119. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190-1203. (Pubitemid 350235027)
120. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13-17.
121. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009;22:508-515.
122. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet. 2003;113:238-243. (Pubitemid 36992282)
123. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008;105:19893-19897.
124. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6:3314-3322.
125. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008;68:3389-3395.
126. Bang Y, Kwak EL, Shaw AT, et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer [abstract]. J Clin Oncol. 2010;28:946S. Abstract 3.
127. National Institutes of Health Clinical Trials database. Available at: http://www.clinicaltrials.gov/. Accessed July 7, 2010.
128. Mento AJ, Martinelli P, Jones RM. Mind mapping in executive education: Applications and outcomes. Journal of Management Development. 1999;18:390-407.